0000062262

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 RECEIVED. SECRETARY OF THE SE

OS FEB 14 PM 3: LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name	···	
Pharmaceutical Research and Man		
2. Address Check if different than previously reported		
1100 15th Street, N.W., Suite 900		
Washington	OC 20005	Ł
3. Principal place of business (if different than line 2)		
City State/2	iip or Country	
4a. Contact Name b. Telephone number	c. E-mail	5. Senate ID#
Mrs. Marjorie Powell 202-835-3517 mpor	well@phrma.org	31350-
7. Client Name Self Pharmaceutical Research and Manufacturers of America		6. House ID # 306540
 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ☐	·	11. No Lobbying A
INCOME OR EXPENSES - Complete Either Line 1 12. Lobbying Firms	2 OR Line 13	
· -	13. Organ	izations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying ac were:	ctivities for this report
Less than \$10,000	Less than \$10,000	
\$10,000 or more	\$10,000 or more 🗵	7,220,000
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all	14. REPORTING METHOD. Che accounting method. See instruction	
payments to the registrant by any other entity for lobbying activities on behalf of the client).		ts using LDA definitions ts under section 6033(b)
		ts under section 162(e) a
		Edit Form >
Signature Mayou Savell		
Signature		uly 13.

O

ŀ	ſ
Ľ	C
Č	١
ľ	١,
Ĺ	Ĺ
¢	
Ċ	
Ĺ	
Ć	
¢	

Registrant Name -of	narmaceutical Research	and Manufacturers	Client Name	Pharmaceutical Research and Manufa- of America
engaged in lobbyi		ent during the repo	rting period. \	t the general issue areas in which th U sing a separate page for each co
15. General issue	area code BUD - Bud	get/Appropriations		(one per page)
16. Specific lobby	ving issues			
HR 2744-HRe HR 3130 Seco S Rep 109-88, S Rep 109-92,	8, FDA Appropriations, port 109-102, FDA Apport Supplemental FY 2 FDA Appropriations, FDA Appropriations, Y 2006 Budget Recond	oropriations, 2005 Approps, FDA	Appropriations	5,
17. House(s) of C	ongress and Federal a	gencies contacted	Check if	None
Food & Drug Ad House of Repres Senate				
18. Name of each	individual who acted	as a lobbyist in the	is issue area	
First Name	Name Last Name	Suffix	Covered	d Official Position (if applicable)
Lauryl	Dodson		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	······································
Alan	Gilbert		,	
Jason	Grove			
Bryant	Hall	L	egislative Dire	ctor, Sen Bob Graham
Hallie	Maranchick			
Dave	Mohler			
Brian	Nagle			
Peter	Rubin			······································
Peter	Stein	S	r. Policy Advis	or, Sen Santorum
19. Interest of eac	h foreign entity in the	specific issues list	ed on line 16	above 🔀 Check if None

 \Box

LD-2DS (Rev. 4.06)

4	ζ	ľ
Ĺ	1)
ť	١	Į
¢	`	J
Ĺ	ĺ)
ľ,	1)
Ć	÷)
Ĺ)
	•	

Pharmaceutical Research and Manufacturers Registrant Name of America	Client Name _	Pharmaceutical Research and Manufa of America
ADDENDUM for General Lobbying Issue AreaB	UD	
16. Specific lobbying issues (continued from previous	page)	
H. Con. Res. 95-Establishing the congressional budget revising appropriate budgetary levels for fiscal year 200 H.R.4241-Deficit Reduction Act of 2005 Implementation S.1931-Deficit Reduction Omnibus Reconciliation Act of S.Con.Res.18-Budget Resolution)5, and setting for a of Medicare Pr	orth appropriate rescription Drug Modernization Act (
		· .

	Pharmaceutical Research and Manufacturers of
Registrant Name	America

	Pharmaceutical	Research	and	Manufa
Client Name	America			

ADDENDUM for General Lobbying Issue Area BUD

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

First Name Steve	Name Last Name Tilton	Suffix	Covered Official Position (if applicable)
Derrick	White		
	0.0101010101010101010101010101010101010		
······			
)			
11)-(+),)),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			

Add a page to continue additing lobbylets for

©

Ĺ	Ç
Ļ	ľ.
ť	١
ſ	٦
ί	Ľ
Ç	
Ú	
ŧ,	
£	
ŧ	

Registrant Name F	Pharmaceutical Research and Ma	nufacturers Client Name	Pharmaceutical Research and Manufa
engaged in lobby	CTIVITY. Select as many cring on behalf of the client durequested. Attach additional p	odes as necessary to reflecting the reporting period.	t the general issue areas in which th Using a separate page for each co
15. General issue	carea code CPT - Copyright/l	Patent/Trademark	(one per page)
16. Specific lobb	ying issues		
HR 2795, Pat	ent Reform Act of 2005, pater	t issues	
17. House(s) of C	Congress and Federal agencie	s contacted Check if	None
House of Repre Patent and Tra Senate			
18. Name of each	n individual who acted as a lo	obbyist in this issue area	
First Name	Name Last Name S	Covered	d Official Position (if applicable)
Lauryl	Dodson		
Robert	Filippone	Deputy Chief of	Staff, Sen. Robert Graham
Dave	Mohler		
Brian	Nagle		`
Byron	Patterson		
Peter	Rubin		
Derrick	White		
,			
19. Interest of each	ch foreign entity in the specif	ic issues listed on line 16	above Check if None

f	٠,
£	Ľ
¢	•
¢	١,
Ę	Ĺ
Ę	*
Ç	
ť,	-
ĺ,	-

	Pharmaceutical Research			Pharmaceutical Resea	
engaged in lobb	CTIVITY. Select as ying on behalf of the crequested. Attach addi	lient during the re	porting period.		
15. General issu	ne area code HCR - He	ealth Issues	¥	(one per page)	
16. Specific lob	bying issues				
S 184, Safe S 334, Pharr S.4-Healthy	maceutical Market Acce IMPORT Act of 2005 maceutical Market Acce America Act of 2005 and Drug Administratio	ess and Drug Safe			
17 House(s) of	Congress and Federal	aganojos contacto	d Chooleit	FNana	
Department of	Health and Human Servi g Administration	Ü	aClieck ii	i None	. H
	*	•			
18. Name of each	ch individual who acte	d as a lobbyist in	this issue area	e of the first section of the sectio	
First Name	Name Last Name	Suffix		d Official Position (if ap	plicable)
į	Bermingham				
Lauryl	Dodson				
i.	Gilbert				: :
Bryant	Hall				······································
Dave	Möhler	***************************************	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		·····
Brian -	Nagle _				
Byron	Patterson	***************************************			gyggið marannanninga.
Lori	Reilly			Andrews	i.a
Peter	Rubin				

¢	¢
ĺ,	٥
	V
ď	N
Ĺ	O
Ć	
ſ,	
¢	
ſ	*

Pharmaceutical Research and Manufa	acturers of Pharmaceutical Research and Manufa
Registrant Name America	Client Name America

ADDENDUM for General Lobbying Issue Area HCR

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

First Name	Name Last Name Suff	Covered Official Position (if applicable)
Peter	Stein	Sr. Policy Advisor, Sen. Rick Santorum
Steve	Tilton	
Derrick	White	
()		

Form LD-2DS

Ç	ľ
Ĺ	C
(*	
ľ	
Ĺ	
(
¢	
Ç	
Ç	
Ç	ï

Registrant Name of	armaceutical Research and Manufacturer	S Client Name	Pharmaceutical Research and Manufa of America
engaged in lobbyi	TIVITY. Select as many codes as many codes as many codes as many on behalf of the client during the many codes as	eporting period.	
15. General issue	area code MMM - Medicare/Medicaio	<u> </u>	(one per page)
16. Specific lobby	ing issues		
t e	nch Medicare reimbursement issues ficit Reduction Act of 2005 Implement Act of 2003	ation of Medicare	Prescription Drug and
Agency for Healt	ongress and Federal agencies contact th Care Research and Quality care and Medicaid Services, Dept of Heal	<u> </u>	
	individual who acted as a lobbyist in		
First Name	Name Last Name Suffix	1	d Official Position (if applicable)
Maya	Bermingham		
Sharon	Brigner		
Randy	Burkholder		
Lauryl	Dodson		
Robert	Filippone	Deputy Chief of	Staff, Sen. Robert Graham
Alan	Gilbert .		
Jason	Grove		
Bryant	Hall		
Ann	Kaplan	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	· · · · · · · · · · · · · · · · · · ·
19. Interest of each	h foreign entity in the specific issues	listed on line 16	above X Check if None

Ø

LD-2DS (Rev. 4.06)

Ç	1
ř	٠,
ŗ	١,
ľ	١,
Ļ	Ľ,
Ç	
	٠.
¢	1
Ĺ	
Č	

	Pharmaceutical Research and Manufacturers of		Pharmaceutical Research and Manufa
Registrant Name	America	Client Name	America

ADDENDUM for General Lobbying Issue Area MMM

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

First Name	Name Last Name Suffix	Covered Official Position (if applicable)
Hallie	Maranchick	
Dave	Mohler	
Brian	Nagle	
Byron	Patterson	
Peter	Rubin	
Richard	Smith	
Peter	Stein	Sr. Policy Advisor, Sen. Rick Santorum
Niko	Stemple	
Heather	Strawn	
Steve	Tilton	
Jennifer	Van Meter	
Derrick	White	
		0:110:15
Mimi	Kneuer	Chief of Staff, Rep. Billy Tauzin
Mimi	Kneuer	Chief of Staff, Rep. Billy Tauzin
Mimi	Kneuer	
Mimi		
Mimi	Kneuer	
Mimi		

77	
۲	
\wedge	
<u>رم</u>	
Œ	
Ç	
C,	
(:	
C	۱

Registrant Name	Pharmaceutical Research and Manufactuof America	rers Client Name Pharmaceutical R	esearch and Manufa
engaged in lobb		s necessary to reflect the general issue reporting period. Using a separate	
15. General issu	te area codeTAX - Taxation/Internal	Revenue Code (one per pag	e)
16. Specific lob	bying issues		
	vestment in America Act of 2005, R & tment in America Act of 2005, R & D		
17. House(s) of	Congress and Federal agencies cont	acted Check if None	
House of Rep	resentatives		
18. Name of eac	ch individual who acted as a lobbyis	t in this issue area	
First Name	Name Last Name Suffix	Covered Official Position (if applicable)
Bryant	Hall		
Dave	Mohler	2 min 1 min	
Peter	Rubin		
Peter	Stein	Sr. Policy Advisor, Sen. Rick Sar	
Derrick	White		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
			······································
19. Interest of ea	ach foreign entity in the specific issu	es listed on line 16 above Check	ifNone

©

ng on behalf of the cl		necessary to reflect the general issue areas in which th
uested. Attach addit	_	reporting period. Using a separate page for each co s needed.
area code	ts	(one per page)
ing issues		
sioShield Act of 2004,	Liability provis	ons
ongress and Federal a	agencies conta	cted Check if None
individual who acted Name Last Name Bermingham	d as a lobbyist Suffix	Covered Official Position (if applicable)
Stein		Sr. Policy Advisor, Sen. Rick Santorum
Strawn		
	ing issues ioShield Act of 2004, ongress and Federal a individual who acted Name Last Name Bermingham Stein	individual who acted as a lobbyist Name Last Name Suffix Bermingham

ţſ
۲×
\wedge
Ċ
Œ
(=
C_{i}
(
C

Registrant Name F	Pharmaceutical Research	and Manufacturers	Client Name	Pharmaceutical Research and Manufa
engaged in lobby		ient during the re	ecessary to reflece	t the general issue areas in which th Using a separate page for each co
15. General issue	e area code	de (Domestic & F	Foreign)	(one per page)
16. Specific lobb	ying issues			
Strengthening	g protection of intellecturements implementing	ial Property abro		Implementation Act, CAFTA
17. House(s) of (Congress and Federal a	gencies contact	ed Check if	None
House of Representation Senate U.S. Trade Representation		l as a lobbyist in	this issue area	
	Name	·	1	d Official Position (if applicable)
First Name Robert	Last Name Filippone	Suffix	Deputy Chief o	f Staff, Sen. Robert Graham
Alan	Gilbert			
Hallie	Maranchick			
Dave	Mohler			
Geralyn	Ritter	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Peter	Rubin	***************************************		
Renard	Aron			
Joe	Damond	<u> </u>		
Brian	Toohey			
19. Interest of ea	ch foreign entity in the	e specific issues	listed on line 16	above 🔀 Check if None

LD-2DS (Rev. 4.06)

₹ %
ţ~,
$^{\circ}$
(N
ιņ
(3)
Q
O
0
(3)

Pharmaceutical Research and Manufacturers of		Pharmaceutical Research and Manufa
Registrant Name America	Client Name	America

ADDENDUM for General Lobbying Issue Area TRD

18. Name of each individual who acted as a lobbyist in this issue area (continued from previous page)

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Derrick	White	Sumx	
***************************************			-
1))	•••••		

	101000		\$ #
· · · · · · · · · · · · · · · · · · ·			

	,		
MD(111)			
,		······································	
***************************************			45

O

Ļ	ŕ	ì
ŗ	١,	
Ć	١,	J
¢	`	ı
Ĺ	Ĺ)
ť	*	j
ť)
(٠
Ċ		
ŧ		
	1	

General issue area code				porting period. Using a separate page for e	acł
Add page to continue specific issues description for this use House(s) of Congress and Federal agencies contacted	rmation as request	ed. Attach add	itional page(s) as i	needed.	
House(s) of Congress and Federal agencies contacted Check if None Name of each individual who acted as a lobbyist in this issue area Name Name Suffix Covered Official Position (if applicable)	General issue area	code		(one per page)	
Name of each individual who acted as a lobbyist in this issue area Add a page to continue acteding topby Name Last Name Suffix Covered Official Position (if applicable)	Specific lobbying i	issues		Add page to cominue specific issues description for this i	3 88
Name of each individual who acted as a lobbyist in this issue area Add a page to continue acteding topby Name Last Name Suffix Covered Official Position (if applicable)					
Name of each individual who acted as a lobbyist in this issue area Add a page to continue acteding topby Name First Name Name Suffix Covered Official Position (if applicable)	* * * * * * * * * * * * * * * * * * * *		en Saget e		
Name of each individual who acted as a lobbyist in this issue area Add a page to continue acteding topoy. First Name Name Last Name Suffix Covered Official Position (if applicable)	I(-) -fC				
Name of each individual who acted as a lobbyist in this issue area Name First Name Suffix Covered Official Position (if applicable)	House(s) of Congr	ess and rederal		<u></u>	
Name of each individual who acted as a lobbyist in this issue area Name Name Suffix Covered Official Position (if applicable)					
Name of each individual who acted as a lobbyist in this issue area Name Name Suffix Covered Official Position (if applicable)					•
First Name Name Last Name Suffix Covered Official Position (if applicable)	÷			and the second of the second o	
First Name Name Last Name Suffix Covered Official Position (if applicable)					
First Name Suffix	Name of each indi	vidual who acte	ed as a lobbyist in	this issue area Anto a more to manifest a median to be	٠
	Name of each indi		ed as a lobbyist in	l	
		Name	·	l	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	,,
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
and the control of the	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
1. 2.7.5	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	
Interest of each foreign entity in the specific issues listed on line 16 above Check if None	First Name	Name Last Name	Suffix	Covered Official Position (if applicable)	

 \odot

LD-2DS (Rev. 4.06)

	C
r	٠,
¢	١
	١
Ç	
(F. 5
¢	
¢	
ţ	***
ď	7

Registrant Name	Pharmaceutical Resea	rch and Manufacturers	of Client Name	Pharmaceutica America	l Research and Manufac
Information	n Update Page -	Complete ONLY	where registra		tion has changed.
20. Client new	*****		J		<u> </u>
City			State	Zip Code	Country
21. Client new	v principal place of busi	ness (if different than li	ine 20)		
City 22. New gener	ral description of client	s business or activities	State	Zip Code	Country
LOBBYIST 23. Name of First Name		ted individual who is	s no longer exper		lobbyist for the client
2 Dave	Mohler		4		
AFFILIAT	obbying issues that no	ONS	Find t	he code to sel	ect below.
25. Add the to	ollowing affiliated org	ganization(s)	Address		Principal place of Busin
\$ · · · · · ·	N N	Address C/S/Z Address C/S/Z		S C	(city and state or councity ate Country City ate
	each previously repor	=	•		registrant or client
1		· 2		3	
FOREIGN 27. Add the fo	ENTITIES ollowing foreign entit	es			
Name	Street Address City	Address State/Province Country	Principal place of (city and state of		Amount of contribution for lobbying activities Cli
			City State Cot	untry	
28. Name of ea affiliated or		3	onger owns, <u>or</u> co	5	liated with the registrant

Printed Name and Title Marjorie Powell- Senior Assistant General Counsel